AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1148032 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofenate (MK-185, 1 g/day)
Number of subjects: 23
Study 1148032 — intervention group
Group type: COMPARATOR
Intervention: Clofibrate (2 g/day)
Number of subjects: 23
Study 31084994 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 326
Study 31084994 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 326
Study 31084994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 25866134 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency group (n = 32)
Number of subjects: 68
Study 25866134 — intervention group
Group type: COMPARATOR
Intervention: Nonpatency group (n = 33)
Number of subjects: 68
Study 24094562 — intervention group
Group type: EXPERIMENTAL
Intervention: PLMA with Coopdech BB (group PLMA‐BB, n=50)
Number of subjects: 100
Study 24094562 — intervention group
Group type: COMPARATOR
Intervention: ETT with Coopdech BB (group ETT‐BB, n=50)
Number of subjects: 100
Study 24094562 — intervention group
Group type: EXPERIMENTAL
Intervention: PLMA with Coopdech BB
Number of subjects: 100
Study 24122944 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-7288 (10, 20 mg)
Number of subjects: 56
Study 24122944 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 56
Study 24122944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 20090299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis carrier screening
Number of subjects: 241
Study 18727657 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+MTZ+AMX (metronidazole 400 mg 3 x per day and amoxicillin 500 mg 3 x per day for 14 days)
Number of subjects: 43
Study 18727657 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+MTZ (metronidazole 400 mg 3 x per day for 14 days)
Number of subjects: 43
Study 18727657 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 43
Study 16753310 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 120
Study 16753310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 14583903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (monthly consultations for 6 months)
Number of subjects: 152
Study 14583903 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 152
Study 14583903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention and Usual care
Number of subjects: 152
Study 10963636 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin
Number of subjects: 208
Study 10963636 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and cisplatin
Number of subjects: 208
Study 8765459 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Aloe vera extract 0.5% in a hydrophilic cream
Number of subjects: 60
Study 8765459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7933528 — intervention group
Group type: EXPERIMENTAL
Intervention: L-627 (biapenem) at a dose of 10 mg/kg and 12 mg/kg
Number of subjects: 14
Study 7933528 — intervention group
Group type: EXPERIMENTAL
Intervention: L-627 (biapenem)
Number of subjects: 14
Study 3138879 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 60
Study 3138879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28175295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg followed by 2 mg/kg if necessary)
Number of subjects: 100
Study 28175295 — intervention group
Group type: COMPARATOR
Intervention: Ibutilide (1 mg followed by another 1 mg if necessary)
Number of subjects: 100
Study 28175295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 100
Study 28175295 — intervention group
Group type: COMPARATOR
Intervention: Ibutilide
Number of subjects: 100
Study 27253482 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU of vitamin D3 and 1500 mg of calcium daily; 50,000 IU of ergocalciferol (vitamin D2) weekly for vitamin D deficient and insufficient patients until levels normalized or fractures healed.
Number of subjects: 201
Study 23466269 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU)
Number of subjects: 243
Study 23466269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 21199978 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 410
Study 21199978 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Blocks (BB)
Number of subjects: 410
Study 21199978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 410
Study 19196106 — intervention group
Group type: COMPARATOR
Intervention: Splinting only
Number of subjects: 50
Study 19196106 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinting plus ultrasound (US)
Number of subjects: 50
Study 19196106 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinting plus low-level laser (LLL) therapy
Number of subjects: 50
Study 16946685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy (0.625 mg of conjugated equine estrogens per tablet)
Number of subjects: 57
Study 16946685 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical estrogen therapy (0.625 mg conjugated equine estrogens per 1 g vaginal cream)
Number of subjects: 57
Study 15916107 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Number of subjects: 100
Study 15916107 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet
Number of subjects: 100
Study 15916107 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 100
Study 11709448 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 60
Study 11709448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8842586 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 1 mg gemeprost every 6 hours (Group I)
Number of subjects: 100
Study 8842586 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 0.5 mg gemeprost every 6 hours (Group II)
Number of subjects: 100
Study 8842586 — intervention group
Group type: COMPARATOR
Intervention: Both groups received 5 x 1 mg gemeprost every 3 hours if abortion had not occurred after 24 hours
Number of subjects: 100
Study 8842586 — intervention group
Group type: EXPERIMENTAL
Intervention: Parous women in both groups
Number of subjects: 100
Study 8842586 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (0.5 mg)
Number of subjects: 100
Study 1519677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (642 mg)
Number of subjects: 30
Study 1519677 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (0.5, 1.0, and 2.0 mg.kg‐1)
Number of subjects: 30
Study 1519677 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulphate (0.143 mg.kg‐1)
Number of subjects: 30
Study 6546759 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified open meniscectomy
Number of subjects: 0
Study 6546759 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial arthroscopic meniscectomy
Number of subjects: 0
Study 6546759 — intervention group
Group type: COMPARATOR
Intervention: Conventional meniscectomy
Number of subjects: 0
Study 6546759 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic operation
Number of subjects: 0
Study 30895797 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 21
Study 30895797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29038236 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 5 mg, given three times daily for 5 days
Number of subjects: 120
Study 29038236 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given three times daily for 5 days
Number of subjects: 120
Study 29038236 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 120
Study 26012345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 μg/kg
Number of subjects: 21
Study 26012345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.38 μg/kg
Number of subjects: 21
Study 24016037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine pertubation
Number of subjects: 42
Study 24016037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22535759 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 377
Study 19365139 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D dose decreased
Number of subjects: 345
Study 19365139 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D dose increased
Number of subjects: 345
Study 19365139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamin D groups
Number of subjects: 345
Study 17515459 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder for use of beta-blockers
Number of subjects: 1271
Study 17515459 — intervention group
Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 1271
Study 15601388 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.1 mg/kg)
Number of subjects: 10
Study 15601388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11479778 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidum malicum 12 cH
Number of subjects: 20
Study 11479778 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidum ascorbicum 12 cH
Number of subjects: 20
Study 9533929 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg potassium iodide
Number of subjects: 126
Study 9533929 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg potassium iodide
Number of subjects: 126
Study 9533929 — intervention group
Group type: COMPARATOR
Intervention: No supplementary iodine (control group)
Number of subjects: 126
Study 9369918 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection followed by whole brain irradiation (WBI)
Number of subjects: 0
Study 9369918 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 0
Study 9369918 — intervention group
Group type: COMPARATOR
Intervention: Whole brain irradiation (WBI)
Number of subjects: 0
Study 9369918 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Number of subjects: 0
Study 9369918 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidating WBI after systemic chemotherapy
Number of subjects: 0
Study 2663546 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoro-popliteal grafts
Number of subjects: 59
Study 2663546 — intervention group
Group type: COMPARATOR
Intervention: Femoro-distal grafts
Number of subjects: 59
Study 2663546 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoro-popliteal group
Number of subjects: 59
Study 2663546 — intervention group
Group type: COMPARATOR
Intervention: Femoro-distal group
Number of subjects: 59
Study 2663546 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 1245147 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g L-dopa
Number of subjects: 13
Study 1245147 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g L-dopa and 1.0 g L-tryptophan
Number of subjects: 13
Study 30485516 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples calls (CC)
Number of subjects: 268
Study 30485516 — intervention group
Group type: COMPARATOR
Intervention: Individual calls (IC)
Number of subjects: 268
Study 30485516 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education calls (DE)
Number of subjects: 268
Study 28222947 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Number of subjects: 120
Study 28222947 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization splint therapy following arthrocentesis
Number of subjects: 120
Study 28222947 — intervention group
Group type: COMPARATOR
Intervention: Splint therapy only
Number of subjects: 120
Study 25264665 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance followed by Resistance exercise (E + R)
Number of subjects: 19
Study 25264665 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance followed by Endurance exercise (R + E)
Number of subjects: 19
Study 25264665 — intervention group
Group type: COMPARATOR
Intervention: Control (50 minutes rest)
Number of subjects: 19
Study 23507090 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported prescription filling
Number of subjects: 1026
Study 22674359 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (initiated 48 hours after birth)
Number of subjects: 239
Study 22674359 — intervention group
Group type: COMPARATOR
Intervention: Delayed feeding (began on day 5 postpartum)
Number of subjects: 239
Study 19370371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (40,000 IU per week)
Number of subjects: 36
Study 19370371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16728648 — intervention group
Group type: EXPERIMENTAL
Intervention: LRRK2 G2019S mutation
Number of subjects: 586
Study 16728648 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype analysis
Number of subjects: 586
Study 16728648 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution analysis of G2019S
Number of subjects: 586
Study 16728648 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of G2019S
Number of subjects: 586
Study 15237695 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 101
Study 15237695 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 101
Study 11274308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid initiation (900 mg/day immediately following the placebo lead-in)
Number of subjects: 0
Study 11274308 — intervention group
Group type: COMPARATOR
Intervention: Slow initiation (300 mg day 1, 600 mg day 2, then 900 mg/day)
Number of subjects: 0
Study 9249101 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 28
Study 9249101 — intervention group
Group type: COMPARATOR
Intervention: C (No epidural anesthesia)
Number of subjects: 28
Study 9249101 — intervention group
Group type: EXPERIMENTAL
Intervention: E + D (Dopamine infusion during epidural anesthesia)
Number of subjects: 28
Study 9249101 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (Group E) vs No epidural anesthesia (Group C)
Number of subjects: 28
Study 7685682 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac/misoprostol 50mg/200 micrograms 2 or 3 times daily
Number of subjects: 4
Study 7685682 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 50mg
Number of subjects: 4
Study 3323368 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRC antileprosy vaccine (0.5 x 10(9) or 1.7 x 10(7) bacilli, intradermally)
Number of subjects: 0
Study 30089070 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor induction at 39 weeks 0 days to 39 weeks 4 days
Number of subjects: 6106
Study 30089070 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 6106
Study 27821102 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care fund driven program including mobility and falls prevention classes, DXA scan for bone health examination, and consultation about safety in the living environment.
Number of subjects: 10000
Study 27821102 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care fund driven program
Number of subjects: 10000
Study 27821102 — intervention group
Group type: COMPARATOR
Intervention: Control districts (143 control districts)
Number of subjects: 10000
Study 25561698 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOPE intervention (home visit, care coordination toolkits, case discussions)
Number of subjects: 48
Study 25561698 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 48
Study 25561698 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOPE intervention
Number of subjects: 48
Study 22549879 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept 80 mg
Number of subjects: 241
Study 22549879 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept 160 mg
Number of subjects: 241
Study 22549879 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 241
Study 19900209 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with OloGen implant
Number of subjects: 40
Study 19900209 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy without OloGen implant (control group)
Number of subjects: 40
Study 18559917 — intervention group
Group type: EXPERIMENTAL
Intervention: AG infusion
Number of subjects: 7
Study 18559917 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 7
Study 18559917 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH (100 microg iv as a bolus)
Number of subjects: 7
Study 18559917 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.1 mg/kg iv as a slow bolus)
Number of subjects: 7
Study 15819448 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 210
Study 15819448 — intervention group
Group type: COMPARATOR
Intervention: Cognitive control (rest)
Number of subjects: 210
Study 12461765 — intervention group
Group type: EXPERIMENTAL
Intervention: Waltz-lessons (dance-learning intervention)
Number of subjects: 10
Study 12461765 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched depressed patients)
Number of subjects: 10
Study 10608295 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrinin (100 microg per tablet, every second day)
Number of subjects: 46
Study 10608295 — intervention group
Group type: COMPARATOR
Intervention: Commercially available bioorganic selenium (100 microg selenium per tablet, every second day)
Number of subjects: 46
Study 10608295 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 46
Study 7477801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive‐behavioral, nutritional and antidepressant therapy (7 with amineptine and 6 with fluoxetine)
Number of subjects: 13
Study 1951111 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (15, 30, 45, 60, 75, 90, and 105 mg/24 hours)
Number of subjects: 562
Study 1951111 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (various doses)
Number of subjects: 562
Study 1951111 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (highest dose)
Number of subjects: 562
Study 1951111 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 562
Study 1951111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study 7028786 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 infusion at 0.1 ng/kg per min
Number of subjects: 0
Study 7028786 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 infusion at 0.4 ng/kg per min
Number of subjects: 0
Study 7028786 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 infusion at 2.0 ng/kg per min
Number of subjects: 0
Study 7028786 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle infusion)
Number of subjects: 0
Study 7028786 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated endogenous PGI2 secretion
Number of subjects: 0
Study 7028786 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous PGI2 infusion rates
Number of subjects: 0
Study 31867648 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes
Number of subjects: 0
Study 31867648 — intervention group
Group type: COMPARATOR
Intervention: Normal nicotine content control cigarettes
Number of subjects: 0
Study 28440861 — intervention group
Group type: EXPERIMENTAL
Intervention: Families on Track Integrated Preventive Intervention
Number of subjects: 30
Study 28440861 — intervention group
Group type: COMPARATOR
Intervention: Active control (neuropsychological assessment and personalized community referrals)
Number of subjects: 30
Study 26422633 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE III score
Number of subjects: 745
Study 23932821 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier-start dialysis
Number of subjects: 208
Study 23932821 — intervention group
Group type: COMPARATOR
Intervention: Usual-start dialysis (Control)
Number of subjects: 208
Study 21251624 — intervention group
Group type: EXPERIMENTAL
Intervention: CYPHER sirolimus-eluting coronary stent (SES)
Number of subjects: 712
Study 19059391 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise during long term bed rest (LTBR)
Number of subjects: 11
Study 19059391 — intervention group
Group type: COMPARATOR
Intervention: Long term bed rest (LTBR)
Number of subjects: 11
Study 19059391 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to initial physical activity after LTBR
Number of subjects: 11
Study 17184433 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 59
Study 17184433 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 59
Study 12959951 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg slow-release caffeine (SRC) from recovery day 1 (D1) to D5 (0800)
Number of subjects: 27
Study 12959951 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin (Mlt) on preflight D-1 (1700), flight day D0 (1600), and from D1 to D3 (2300)
Number of subjects: 27
Study 12959951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pbo) at the same times as SRC and Mlt
Number of subjects: 27
Study 12166613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (2.9 mg/kg)
Number of subjects: 0
Study 12166613 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (3.0 mg/kg)
Number of subjects: 0
Study 12166613 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (12.7 mg/kg)
Number of subjects: 0
Study 12166613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (3.0 mg/kg)
Number of subjects: 0
Study 12166613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide and Diclofenac
Number of subjects: 0
Study 12166613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg)
Number of subjects: 0
Study 12166613 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs (Nimesulide, Diclofenac, Celecoxib, Rofecoxib)
Number of subjects: 0
Study 10189045 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate dietary intervention
Number of subjects: 402